1. A novel lipoprotein (a) lowering drug, D-47, decreases neointima thickening after vascular injury
- Author
-
Takashi Oyamada, Kazuo Ogawa, Masataka Sata, Ryuichi Morishita, Nagakatsu Harada, Yutaka Nakaya, Hironori Nakagami, Hiroshi Sakaue, and Daiju Fukuda
- Subjects
0301 basic medicine ,Neointima ,Drug ,Genetically modified mouse ,Male ,medicine.medical_specialty ,media_common.quotation_subject ,Mice, Transgenic ,030204 cardiovascular system & hematology ,General Biochemistry, Genetics and Molecular Biology ,Polyethylene Glycols ,cardiovascular events ,03 medical and health sciences ,Mice ,0302 clinical medicine ,Internal medicine ,Medicine ,Animals ,Humans ,lipoprotein a ,Risk factor ,media_common ,Hypolipidemic Agents ,biology ,business.industry ,General Medicine ,Lipoprotein(a) ,Plasma levels ,Vascular System Injuries ,Pyrrolidinones ,Recombinant Proteins ,Femoral Artery ,030104 developmental biology ,Endocrinology ,biology.protein ,Polyvinyls ,Thickening ,atherosclerosis ,low density lipoprotein ,business ,Hydroxybenzoate Ethers - Abstract
Although Lp(a) have been thought to be a cardiovascular risk factor, it is unclear whether lowering Lp(a) levels reduces the risk of cardiovascular diseases. No pharmacological agents which selectively reduce serum Lp(a) levels, and Lp(a) is present in primate but absent in common laboratory animals such as mice and pigs. In the present study we used transgenic mice of human Lp(a) and tested effect a novel Lp(a) lowering drug D-47 on neointima formation after vascular injury. D-47 successfully decreased plasma levels of Lp(a) and possibly inhibited neointima formation in Lp(a) transgenic mice. The results indicate that we can modulate plasma Lp(a) levels by pharmacologic agents and inhibit atherogenic properties of Lp(a) by reducing plasma levels of Lp(a). J. Med. Invest. 64: 64-67, February, 2017.
- Published
- 2017